This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Novartis AG blocked MSN Laboratories Pvt. Ltd.’s attempt to launch a copy of its blockbuster Entresto before July 16, as a ...

(Reuters) -Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment ...

Key growth drivers include increased healthcare spending, the rise of chronic diseases, and advancements in nanotechnology.

Growth is driven by the aging population, rising chronic diseases, and self-administration practices. Advances in technology, new product launches, and favorable policies bolster growth. Injectable ...

Several companies are advancing treatments for anal cancer, including Merck (KEYTRUDA), BioMimetix (BMX-001), Novartis (KFA115), and Bicara Therapeutics (BCA101), among others. As immunotherapy ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...